Flat panel display TV stand
    31.
    发明申请
    Flat panel display TV stand 审中-公开
    平板显示电视架

    公开(公告)号:US20060214072A1

    公开(公告)日:2006-09-28

    申请号:US11376933

    申请日:2006-03-16

    申请人: Kyung Lee

    发明人: Kyung Lee

    IPC分类号: F16M11/00 G09G3/28

    CPC分类号: F16M13/02 F16M11/046

    摘要: A flat panel display TV stand makes it possible to stably install a TV equipped with a flat panel display (e.g. LCD or PDP) regardless of the type of wall (e.g. concrete wall, gypsum board wall, or wooden wall), on which the TV is to be installed, as well as the size of the TV. The stand can fully support the weight of the TV and hides wires and cables drawn from the TV. This provides an aesthetic appearance. In addition, the stand can additionally accommodate peripheral devices (e.g. DVD player or VCR), which are typically used together with the TV. As such, the stand can be used for various purposes.

    摘要翻译: 平板显示电视架可以稳定地安装配有平板显示器(例如LCD或PDP)的电视机,而不管墙壁类型(例如混凝土墙壁,石膏板墙壁或木墙),电视机 要安装,以及电视的大小。 支架可以完全支持电视的重量,并隐藏从电视机中抽出的电线和电缆。 这提供了审美的外观。 此外,支架还可以容纳通常与电视一起使用的外围设备(例如DVD播放器或VCR)。 因此,支架可用于各种目的。

    Multilayer-coated stent for controlled drug release and manufacturing method thereof
    33.
    发明申请
    Multilayer-coated stent for controlled drug release and manufacturing method thereof 有权
    用于受控药物释放的多层涂层支架及其制造方法

    公开(公告)号:US20060161242A1

    公开(公告)日:2006-07-20

    申请号:US11210807

    申请日:2005-08-25

    IPC分类号: A61F2/82 B05D1/02

    摘要: The present invention provides a multilayer-coated stent for controlled drug release, comprising: a first base layer formed on a stent support and made of poly(ethylene-co-vinylacetate) or polystyrene-ethylene-butylene rubber polymer; a second coating layer formed on the first base layer and made of a biocompatible or a bioabsorbable polymer and a drug component; and a third coating layer formed on the second coating layer and made of a biocompatible or a bioabsorbable polymer and a drug component different from the drug component of the second coating layer. The inventive stent can deliver a broad range of therapeutic substances for a long time and prevent the early rapid release of the drug components in blood. Also, unlike the existing drug-coated stents, the inventive stent includes two kinds of drugs complementary to each other, but can optimize the efficacy of the drugs by differentiating the control of drug release according to time.

    摘要翻译: 本发明提供一种用于受控药物释放的多层涂层支架,包括:形成在支架上并由聚(乙烯 - 共 - 乙酸乙烯酯)或聚苯乙烯 - 乙烯 - 丁烯橡胶聚合物制成的第一基层; 形成在第一基底层上并由生物相容或生物可吸收的聚合物和药物成分制成的第二涂层; 以及形成在第二涂层上并由生物相容性或生物可吸收聚合物和不同于第二涂层的药物成分的药物成分制成的第三涂层。 本发明的支架可以长时间传递广泛的治疗物质,并且防止血液中药物成分的早期快速释放。 此外,与现有的药物涂层支架不同,本发明的支架包括彼此互补的两种药物,但可以通过根据时间区分药物释放的控制来优化药物的功效。

    Thin film transistor substrate of poly-silicon type and method of fabricating the same
    34.
    发明申请
    Thin film transistor substrate of poly-silicon type and method of fabricating the same 有权
    多晶硅薄膜晶体管基板及其制造方法

    公开(公告)号:US20060092342A1

    公开(公告)日:2006-05-04

    申请号:US11152102

    申请日:2005-06-15

    申请人: Kyung Lee

    发明人: Kyung Lee

    IPC分类号: G02F1/1343

    摘要: A poly-silicon type thin film transistor substrate includes: a plurality of gate lines and data lines defining a pixel; a pixel electrode in the pixel; a thin film transistor having a gate electrode connected to one of the gate lines, a source electrode connected to one of the data lines, a drain electrode connected to the pixel electrode, and a first active layer of poly-silicon defining a channel between the source electrode and the drain electrode; and at least two storage lines positioned on different sides of the pixel electrode.

    摘要翻译: 多晶硅型薄膜晶体管基板包括:限定像素的多条栅极线和数据线; 像素中的像素电极; 薄膜晶体管,具有连接到栅极线之一的栅电极,连接到数据线中的一条线的源电极,连接到像素电极的漏电极和多晶硅的第一有源层,其在第 源电极和漏电极; 以及位于像素电极的不同侧上的至少两个存储线。

    Method for the detection of factor XIII in plasma
    38.
    发明授权
    Method for the detection of factor XIII in plasma 失效
    血浆中XIII因子检测方法

    公开(公告)号:US5015588A

    公开(公告)日:1991-05-14

    申请号:US114630

    申请日:1987-10-29

    IPC分类号: C12Q1/56 G01N33/86

    摘要: An assay method for the detection of Factor XIII in plasma is disclosed in which a primary amine derivative of biotin such as preferably 5-(biotinamido) pentylamine is incubated with a glutamine substrate and activated Factor XIII (Factor XIIIa) to form a biotinylated product which may be measured by convention detection assays. In a preferred embodiment, the biotinylated product is bound to a well in a microtiter plate or other solid support and the product is measured by a colorimetric assay which may be read by an automated spectrophotometric plate reader.

    摘要翻译: 公开了一种用于检测血浆中因子XIII的测定方法,其中生物素的伯胺衍生物如优选5-(生物素酰氨基)戊胺与谷氨酰胺底物和活化因子XIII(因子XIIIa)一起孵育以形成生物素化产物, 可以通过常规检测测定来测量。 在优选的实施方案中,生物素化的产物在微量滴定板或其它固体支持物中与孔结合,并且通过比色测定法测量产物,其可以通过自动分光光度计读数器读取。

    Methods of screening for inhibitors of antiplasmin cleaving enzyme
    39.
    发明申请
    Methods of screening for inhibitors of antiplasmin cleaving enzyme 审中-公开
    筛选抗肿瘤酶切割酶抑制剂的方法

    公开(公告)号:US20080118933A1

    公开(公告)日:2008-05-22

    申请号:US11986058

    申请日:2007-11-20

    IPC分类号: G01N33/53 C12N9/68

    摘要: Human α2-antiplasmin (α2AP) is the major inhibitor of the proteolytic enzyme plasmin that digests fibrin. Two forms of α2AP circulate in human plasma: a 464-residue protein, which we have termed “pro”-form, or α2APpro and an N-terminally-shortened 452-residue “activated”-form, or α2APact. The latter becomes crosslinked to fibrin by activated factor XIII about 5-fold more rapidly than α2APpro and makes fibrin resistant to digestion by plasmin. A new human plasma proteinase has been identified herein that cleaves the Pro12-Asn13 bond of α2APpro to yield α2APact. This enzyme is identified herein as Antiplasmin Cleaving Enzyme (APCE). Novel inhibitors of circulating APCE can diminish α2AP inhibitory capacity within forming fibrin or blood clots thereby making fibrin deposits or blood clots more susceptible to removal by plasmin. Patients who are susceptible to atherosclerotic plaque formation or are susceptible to developing thrombi that compromise organ function will benefit by therapies providing such inhibitors on a long term basis.

    摘要翻译: 人α2 - 对映体蛋白(α2 AP)是消化纤维蛋白的蛋白水解酶纤溶酶的主要抑制剂。 两种形式的α2 AP在人血浆中循环:464残基的蛋白质,我们称之为“亲”型或α2亚基 / SUB>和N-末端缩短的452残基“活化”形式或α2亚类作用。 后者通过活化因子XIII与α2 P肽相比快速交联5倍,并使纤维蛋白对纤溶酶消化具有抗性。 本文已经鉴定了一种新的人血浆蛋白酶,其切割了α2 -ATP pro pro的Pro12-Asn13键,以产生α2亚基 。 该酶在本文中被鉴定为抗血小板裂解酶(APCE)。 循环APCE的新型抑制剂可以降低形成纤维蛋白或血凝块中的α2 AP抑制能力,从而使纤维蛋白沉积物或血块更容易被纤溶酶去除。 易受动脉粥样硬化斑块形成或容易发生危及器官功能的血栓的患者将通过长期提供这种抑制剂的疗法而受益。

    Furancarbonylguanidine Derivatives, Their Preparation and Pharmaceutical Compositions Containing Them
    40.
    发明申请
    Furancarbonylguanidine Derivatives, Their Preparation and Pharmaceutical Compositions Containing Them 失效
    呋喃羰基胍衍生物,它们的制备和含有它们的药物组合物

    公开(公告)号:US20070299131A1

    公开(公告)日:2007-12-27

    申请号:US10581799

    申请日:2004-12-24

    CPC分类号: C07D307/68

    摘要: The present invention relates to furancarbonylguanidine derivatives, a preparation method thereof and a pharmaceutical composition comprising the same. Furancarbonylguanidine derivatives of the present invention inhibit NHE-1 (sodium-hydrogen exchanger isoform 1), which helps recovery of heart function damaged from ischemia/reperfusion and decreases myocardial infarction rate, indicating that they have protective effect on myocardial cells. Thus, furancarbonylguanidine derivatives of the present invention can be effectively used for the prevention and the treatment of ischemic heart diseases such as myocardial infarction, arrhythmia, angina pectoris, etc, and also a promising candidate for a heart protecting agent applied to reperfusion therapy including thrombolytics or cardiac surgery including coronary artery bypass graft, percutaneous transluminal coronary angioplasty, etc.

    摘要翻译: 本发明涉及呋喃羰基胍衍生物,其制备方法和包含其的药物组合物。 本发明的呋喃羰基胍衍生物抑制NHE-1(钠氢交换异构体1),其有助于恢复从缺血/再灌注损伤的心脏功能,并降低心肌梗死率,表明它们对心肌细胞具有保护作用。 因此,本发明的呋喃羰基胍衍生物可以有效地用于预防和治疗心肌梗死,心律失常,心绞痛等缺血性心脏病,也是应用于再灌注治疗的心脏保护剂的有希望的候选物,包括溶栓剂 或心脏手术,包括冠状动脉旁路移植术,经皮腔内冠状动脉血管成形术等